Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for biotechnology industry professionals · Thursday, March 28, 2024 · 699,442,004 Articles · 3+ Million Readers

CytoDyn Announces Investment Community Conference Call for October 19, 2017

VANCOUVER, Washington, Oct. 17, 2017 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new antibody therapies for combating human immunodeficiency virus (HIV) infection, announces that management will hold an investment community conference call on Thursday, October 19, 2017, at 1:00 p.m. PT / 4:00 p.m. ET to discuss the Company’s recent meeting with the FDA and other clinical trial and regulatory developments.

Conference Call and Webcast Instructions
Interested participants and investors may access this conference call by dialing 877-407-2986 (U.S./Canada) or 201-378-4916 (international).

A live audio webcast may also be accessed via CytoDyn’s corporate website at www.cytodyn.com under the Investors section/IR Calendar and will be archived for 60 days.  Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download and install any necessary software.  The webcast can also be accessed via the following link:  http://cytodyn.equisolvewebcast.com/10-19-17.

A replay of the conference call will be available until December 19, 2017.  To access the replay, interested parties may dial 877-660-6853 (U.S./Canada) or 201-612-7415 (international); Conference ID: 13672522.

CONTACTS:
Investors:
LHA Investor Relations
Jody Cain
Phone: 310-691-7100
E-mail: jcain@lhai.com

Media:
Joan E. Kureczka
Bioscribe, Inc.
Phone: 415-821-2413
Email: Joan@bioscribe.com

Primary Logo

Powered by EIN News
Distribution channels: Conferences & Trade Fairs


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release